<DOC>
	<DOCNO>NCT01442714</DOCNO>
	<brief_summary>Primary Objective : - Determine lack disease progression ( CR/CRi/PR/HI rate ) 6 cycle treatment combination azacitidine plus lenalidomide previously treat patient Acute Myeloid Leukemia ( AML ) high-risk Myelodysplastic Syndromes ( HR-MDS ) . Secondary Objective : - Determine 42-day survival treatment combination elderly patient previously treat AML/HR-MDS patient</brief_summary>
	<brief_title>Azacitidine + Lenalidomide Combo Elderly Previously Treated Acute Myeloid Leukemia ( AML ) &amp; High-Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>To eligible participate study , patient must meet follow criterion ( principal investigator ' discretion ) : AML ( accord WHO 2008 classification ) , include : de novo secondary AML previously treat demethylating agent AML secondary AML previously treat demethylating agent MDS de novo secondary AML previously treat high dose lenalidomide AML ( &gt; =25mg ) High Risk MDS , include Del ( 5q ) nondel ( 5q ) , previously treat lenalidomide . novo secondary HRMDS previously treat demethylating agent White blood cell count ( WBC ) initiation treatment &lt; = 10,000 If WBC &gt; = 10,000 patient may start appropriate dose hydroxyurea ( determined investigator ) , WBC &lt; 10,000 , time hydroxyurea discontinue 24 hour prior enrollment Age &gt; = 60 immediate candidate allogeneic stem cell transplantation Unwilling unable receive conventional chemotherapy Prior therapy , either single agent demethylator ( 5Azacitidine Decitabine ) and/or Lenalidomide ECOG performance status &lt; = 2 ( See Appendix C definition ) Life expectancy &gt; = 2 month All study participant must register mandatory RevAssist program , willing able comply requirement RevAssist Females childbearing potential ( FCBP ) â€  must negative serum urine pregnancy test sensitivity least 50 mIU/mL 1014 day prior study enrollment within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin two acceptable method birth control , one highly effective method one additional effective method time , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . ( See Appendix A : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods ) . Willing able understand voluntarily sign write informed consent Able adhere study visit schedule protocol requirement Patients meet follow criterion exclude study : Patients LRMDS ( lowrisk Myelodysplastic Syndromes ) progress HRMDS low dose lenalidomide 5day azacitidine eligible . History intolerance thalidomide development erythema nodosum take thalidomide similar drug Known suspected hypersensitivity azacitidine mannitol Patients advance malignant hepatic tumor . Concomitant treatment antineoplastic agent , exception hydroxyurea Previous participation VIREL study concomitant use azacitidine plus lenalidomide . Antineoplastic treatment less four week prior enrollment , exception hydroxyurea Use experimental drug therapy within 28 day baseline Inability swallow absorb drug Active opportunistic infection treatment opportunistic infection within four week first day study drug dose New York Heart Association Class III IV heart failure Unstable angina pectoris Uncontrolled cardiac arrhythmia Uncontrolled psychiatric illness would limit compliance requirement Known HIV infection Pregnant breast feeding female ; lactate female must agree breast feed take lenalidomide Other medical psychiatric illness organ dysfunction laboratory abnormality opinion investigator would compromise patient 's safety interfere data interpretation Laboratory abnormality : Either creatinine &gt; =1.5 mg/dL creatinine clearance &lt; =50 mL/min Total bilirubin &gt; = 1.5 x institutional ULN ( Upper limit normal ) ( unless document Gilbert 's syndrome ) AST ( Aspartate Aminotransferase ) ALT ( Alanine Aminotransferase ) &gt; = 2.5 x institutional ULN</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>